Lead Sponsor

Ruijin Hospital

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1: Patients should be ≥18 years old at diagnosis
•2: Diagnosed as MCL or CLL who have received at least one prior therapy and CLL patients should be enrolled after the approval of NMPA (according to Chinese label)
•3: Eligible for acalabrutinib treatment assessed by investigators (physician's evaluation) in clinical practice
•4: Patient/legal guardian must be able to read, understand, and sign the informed consent form (ICF)

•1: Ineligible for acalabrutinib treatment assessed by investigators (physician's evaluation)
•2: Progression after accepting other BTKi treatment before use of acalabrutinib
•3: Concurrent participation in another interventional clinical study
•4: Females of childbearing potential must practice highly effective contraception during treatment of acalabrutinib, and for at least 1 week after the last dose of acalabrutinib, and have a negative urine or serum pregnancy test ≤ 7 days before the first dose of study drug(s).
•5: No requirement to use contraception for male subjects treated with acalabrutinib. a. A sterile male is considered a highly effective contraception method for female patients. b. Males with known "low sperm counts" (consistent with "sub-fertility") are not to be considered sterile for purposes of this study.

Related studies

NCT07221500 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

NCT06846671 · CLL, Chronic Lymphocytic Leukemia

NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more

NCT07030400 · Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)

NCT06859424 · AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), and more

Real-world Study of Acalabrutinib